Literature DB >> 21412926

Congenital anomalies and rhabdoid tumor associated with 22q11 germline deletion and somatic inactivation of the SMARCB1 tumor suppressor.

George Toth1, Claudia B Zraly, Tricia L Thomson, Carolyn Jones, Shawn Lapetino, Jonathan Muraskas, Jiwang Zhang, Andrew K Dingwall.   

Abstract

The most common microdeletion in humans involves the 22q11 region. Congenital anomalies associated with 22q11 loss include cardiac and facial defects. Less frequent is the co-presentation of malignant rhabdoid tumors that are highly aggressive childhood malignancies typically found in renal or extra-renal soft tissues and central nervous system. A newborn patient presented with multiple congenital anomalies consistent with 22q11 deletion syndrome including cleft lip and palate, ear tags and ventricular septal defects co-presenting with an axillary rhabdoid tumor. Comparative genomic hybridization revealed a 2.8 Mb germline deletion in the 22q11.2 region containing genes required for normal fetal development and the SMARCB1 tumor suppressor gene. Analysis of tumor DNA revealed a somatic deletion of exon 7 in the second allele of SMARCB1. Expression of SMARCB1 was absent, while tumor markers including MYC, GFAP, and CLAUDIN-6 were upregulated. The presence of tandem oriented BCRL modules located within interspersed low copy repeat elements throughout the 22q11 distal region may predispose this area for microdeletions through nonalleleic homologous recombination.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21412926      PMCID: PMC3075385          DOI: 10.1002/gcc.20862

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  55 in total

1.  Timed mutation and cell-fate mapping reveal reiterated roles of Tbx1 during embryogenesis, and a crucial function during segmentation of the pharyngeal system via regulation of endoderm expansion.

Authors:  Huansheng Xu; Fabiana Cerrato; Antonio Baldini
Journal:  Development       Date:  2005-09-01       Impact factor: 6.868

Review 2.  Molecular diagnostics of CNS embryonal tumors.

Authors:  Stefan M Pfister; Andrey Korshunov; Marcel Kool; Martin Hasselblatt; Charles Eberhart; Michael D Taylor
Journal:  Acta Neuropathol       Date:  2010-09-30       Impact factor: 17.088

3.  Trastuzumab activates allogeneic or autologous antibody-dependent cellular cytotoxicity against malignant rhabdoid tumor cells and interleukin-2 augments the cytotoxicity.

Authors:  Yoshiki Katsumi; Yasumichi Kuwahara; Shinichi Tamura; Ken Kikuchi; Osamu Otabe; Kunihiko Tsuchiya; Tomoko Iehara; Hiroshi Kuroda; Hajime Hosoi; Tohru Sugimoto
Journal:  Clin Cancer Res       Date:  2008-02-15       Impact factor: 12.531

4.  Rhabdoid tumor: gene expression clues to pathogenesis and potential therapeutic targets.

Authors:  Samantha Gadd; Simone Treiger Sredni; Chiang-Ching Huang; Elizabeth J Perlman
Journal:  Lab Invest       Date:  2010-03-08       Impact factor: 5.662

5.  Loss of protein kinase C delta gene expression in human squamous cell carcinomas: a laser capture microdissection study.

Authors:  Vipin Yadav; Nicole C Yanez; Sarah E Fenton; Mitchell F Denning
Journal:  Am J Pathol       Date:  2010-01-21       Impact factor: 4.307

6.  Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood.

Authors:  L B Rorke; R Packer; J Biegel
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

7.  A new syndrome involving cleft palate, cardiac anomalies, typical facies, and learning disabilities: velo-cardio-facial syndrome.

Authors:  R J Shprintzen; R B Goldberg; M L Lewin; E J Sidoti; M D Berkman; R V Argamaso; D Young
Journal:  Cleft Palate J       Date:  1978-01

Review 8.  Genetic modifiers of the physical malformations in velo-cardio-facial syndrome/DiGeorge syndrome.

Authors:  Vimla S Aggarwal; Bernice E Morrow
Journal:  Dev Disabil Res Rev       Date:  2008

Review 9.  The role of SMARCB1/INI1 in development of rhabdoid tumor.

Authors:  Charles W M Roberts; Jaclyn A Biegel
Journal:  Cancer Biol Ther       Date:  2009-03-29       Impact factor: 4.742

Review 10.  A deletion and a duplication in distal 22q11.2 deletion syndrome region. Clinical implications and review.

Authors:  Luis Fernández; Julián Nevado; Fernando Santos; Damià Heine-Suñer; Victor Martinez-Glez; Sixto García-Miñaur; Rebeca Palomo; Alicia Delicado; Isidora López Pajares; María Palomares; Luis García-Guereta; Eva Valverde; Federico Hawkins; Pablo Lapunzina
Journal:  BMC Med Genet       Date:  2009-06-02       Impact factor: 2.103

View more
  4 in total

1.  Claudin-6 is a nonspecific marker for malignant rhabdoid and other pediatric tumors.

Authors:  Lisa M Sullivan; Theresa Yankovich; Paul Le; Daniel Martinez; Mariarita Santi; Jaclyn A Biegel; Bruce R Pawel; Alexander R Judkins
Journal:  Am J Surg Pathol       Date:  2012-01       Impact factor: 6.394

2.  Significant evidence of linkage for a gene predisposing to colorectal cancer and multiple primary cancers on 22q11.

Authors:  Craig Teerlink; Quentin Nelson; Randall Burt; Lisa Cannon-Albright
Journal:  Clin Transl Gastroenterol       Date:  2014-02-27       Impact factor: 4.488

3.  Genetic variants in Forkhead box O1 associated with predisposition to sepsis in a Chinese Han population.

Authors:  Huijuan Wang; Zhaohui Tong; Jia Li; Kun Xiao; Feifei Ren; Lixin Xie
Journal:  BMC Infect Dis       Date:  2019-09-06       Impact factor: 3.090

4.  Current recommendations for clinical surveillance and genetic testing in rhabdoid tumor predisposition: a report from the SIOPE Host Genome Working Group.

Authors:  M C Frühwald; K Nemes; H Boztug; M C A Cornips; D G Evans; R Farah; S Glentis; M Jorgensen; K Katsibardi; S Hirsch; K Jahnukainen; I Kventsel; K Kerl; C P Kratz; K W Pajtler; U Kordes; V Ridola; E Stutz; F Bourdeaut
Journal:  Fam Cancer       Date:  2021-02-03       Impact factor: 2.375

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.